Toripalimab combined with chemotherapy is a clinically valuable and important regimen in the treatment of extensive-stage small-cell lung cancer (ES-SCLC).
However, there are no studies on the cost-effectiveness of this regimen, so this study was designed to evaluate the cost-effectiveness of Toripalimab regimen for the treatment of ES-SCLC from the perspectives of the Chinese health system and the U.S. health system, respectively.
